MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) will release its first-quarter 2022 financial results after market close on May 3, 2022. The company will also host a conference call at 4:30 PM ET that same day to discuss the results and recent corporate developments. Interested parties can access the call by dialing (877) 303-6253 for domestic calls or (973) 409-9610 for international calls, using Conference ID# 6791448. A webcast will be available in the Investor Relations section of their website, with a replay accessible for 30 days post-call.
- Upcoming conference call to discuss financial results and corporate progress.
- None.
ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2022 after the market closes on Tuesday, May 3, 2022. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 3, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 6791448.
The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
When will MacroGenics release its first-quarter 2022 financial results?
What time is the conference call for MacroGenics' financial results?
How can I listen to the MacroGenics conference call?
Where can I find the webcast of the MacroGenics conference call?
